Skip to main content

Dogwood Therapeutics, Inc.

corporate_fare Company Profile

Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed DWTX - Latest Insights

DWTX
Apr 27, 2026, 2:30 PM EDT
Filing Type: DEF 14A
Importance Score:
9
DWTX
Apr 17, 2026, 5:26 PM EDT
Filing Type: PRE 14A
Importance Score:
9
DWTX
Apr 15, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
DWTX
Mar 26, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
DWTX
Mar 18, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
DWTX
Mar 18, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
DWTX
Mar 18, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
DWTX
Mar 12, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
DWTX
Jan 23, 2026, 4:30 PM EST
Filing Type: PRE 14A
Importance Score:
8
DWTX
Jan 20, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
DWTX
Jan 15, 2026, 4:19 PM EST
Filing Type: S-3
Importance Score:
8
DWTX
Jan 13, 2026, 12:38 PM EST
Filing Type: 8-K
Importance Score:
8
DWTX
Jan 13, 2026, 12:06 PM EST
Filing Type: 424B5
Importance Score:
8